Article

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma

Department Oncology, Finsen Centre/National University Hospital, 9 Blegdamsvej, Copenhagen DK-2100, Denmark.
British Journal of Cancer (Impact Factor: 4.82). 08/2008; 99(1):44-50. DOI: 10.1038/sj.bjc.6604421
Source: PubMed

ABSTRACT The aim was to evaluate the activity of cisplatin and vinorelbine in previously untreated, inoperable patients having histologically verified malignant pleural mesothelioma (MPM), normal organ function, and performance status 0-2. Treatment was vinorelbine 25 mg m(-2) i.v. weekly and cisplatin 100 mg m(-2) i.v. every 4 weeks with hydration and standard prophylactic antiemetic treatment. Patients gave written informed consent. Characteristics of 54 consecutive patients were: males 85%, epithelial subtype 74%, IMIG stages III and IV 35 and 46%, performance status 0, 1, and 2, 26, 69, and 6%, and median age 63 years (31-78 years). CTC grade 3 or 4 toxicity occurred with respect to leukocytopenia (48% of patients, grade 4 in 13%), nausea (13%), neurotoxicity (11%), nephrotoxicity (4%), and other toxicities (9%). There were no toxic deaths. The median number of cycles was four. The fraction of patients alive at 1-, 2-, and 3-years were 61, 31, and 4%, respectively, and median survival and median time to progression were 16.8 months (0.5 to 46.4 +months) and 7.2 months (1.6 to 40.6 + months). There were two CRs and 14 PRs (response rate 29.6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported.

Download full-text

Full-text

Available from: Jens Benn Sørensen, May 22, 2014
0 Followers
 · 
113 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chemotherapy based on platinum is the standard treatment for unresectable malignant pleural mesothelioma (MPM). Liposomal doxorubicin (LD) consists of pegylated phospholipid vesicles that encapsulate doxorubicin-enhancing liposome deposition in the tumour. We evaluated the toxicity profile and anti-tumour activity of cisplatin plus LD in untreated patients with MPM, as well as (99m)Tc-LD distribution in MPM lesions after chemotherapy administration. A total of 38 patients with non-resectable MPM received LD 40 mg m(-2) and cisplatin 60 mg m(-2) every 21 days. Gamma camera images of (99m)Tc-LD were acquired to evaluate LD accumulation in measurable tumour tissue. The study was registered in Clinical Trials (NCT00886028). In all, 72% of patients were stage III and 28% were stage IV. Eighty four percent and 16% have high and low risk acording EORTC respectively. The median time to progression was 4.6 months (95% confidence interval (95% CI: 3.4-5.9 months), and median overall survival (OS) was 19.6 months (15.2-37.2 months). Patients that responded to chemotherapy treatment had better survival than patients who did not. Functional physical scales, dysnea, cough, and chest/arm pain demonstrated improvement. The accumulation ratio of LD in tumour and soft tissues vs liver was 0.78±0.16 and 0.29±0.09, respectively. After 1 h of administration, LD uptake in tumour tissue was higher than in soft tissue (P< 0.001). The combination of LD and cisplatin results in an active therapeutic regimen for unresectable MPM, with an acceptable toxicity profile and improvement in quality of life. (99m)Tc-LD showed higher levels of tumour uptake as compared with surrounding tissues.
    British Journal of Cancer 02/2012; 106(6):1027-32. DOI:10.1038/bjc.2012.44 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Chemotherapie ist essenzieller Bestandteil sowohl kurativer als auch palliativer Behandlungskonzepte beim malignen Pleuramesotheliom (MPM). Bei der Mehrzahl der Patienten sind aufgrund des Ausbreitungsgrads der Erkrankung, ihres Alters bzw. vorhandener Komorbiditäten nur palliative Behandlungsoptionen möglich. Standard in der Erstlinientherapie ist die Kombination von Pemetrexed und Cisplatin, die zu einer signifikanten Verlängerung des Überlebens sowie zur Verbesserung der Lebensqualität bei gebesserter Lungenfunktion und tumorbedingter Symptome führt. Mit zunehmender Detektion molekularer Besonderheiten des MPM wächst die Zahl zielgerichteter Substanzen, die erfolgversprechend in Studien geprüft werden. Die Strahlentherapie spielt in der palliativen Behandlung des MPM eine untergeordnete Rolle. Der Stellenwert einer prophylaktischen Stich- oder Drainagekanalbestrahlung ist nicht geklärt. Die Talkumpleurodese zur Beseitigung ausgedehnter, rezidivierender Pleuraergüsse und eine kombinierte analgetische Behandlung sind feste Bestandteile des palliativen Managements beim MPM. Dieser Artikel gibt einen Überblick über Standards in der medikamentösen, insbesondere der palliativen systemischen Therapie des MPM, neue Substanzen und symptomorientierte Behandlungsoptionen. Chemotherapy is an essential part not only for curative but also for palliative treatment concepts for malignant pleural mesothelioma (MPM). For the majority of patients with MPM palliative forms of treatment are the only option due to the extent of the disease, their age or the presence of comorbidities. The standard first line chemotherapy is the combination of pemetrexed and cisplatin which not only leads to a significant extension of survival but also to an improvement of quality of life with better lung function and reduction of tumor-linked symptoms. With increasing detection of molecular characteristics of MPM the number of targeted agents increases which show promising results in trials. Radiotherapy plays a subordinate role in the palliative treatment of MPM. The significance of prophylactic radiation of puncture or drainage canals has not been clarified. Talc pleurodesis for the elimination of extensive, relapsing pleural effusion and a combined analgetic treatment are integral components of the palliative management of MPM. This article provides an overview of standards in medicinal, especially palliative systematic therapy of MPM, new substances and symptom-oriented treatment options.
    Der Pneumologe 01/2009; 7(1):36-42. DOI:10.1007/s10405-009-0351-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Two patients with primary peritoneal mesothelioma are reported. They had abdominal symptoms, no symptoms referable to the respiratory system and normal chest X-rays. There was no clinical evidence of impaired respiratory function. One of the patients had a history of brief asbestos exposure over 20 years before diagnosis. The procedure for obtaining compensation is outlined and the protean uses of, and hence possible exposure to, asbestos are noted. In screening programmes consideration should be given to both pulmonary and abdominal symptoms. Laparoscopy may have a part to play in earlier diagnosis of peritoneal mesothelioma.
    British Journal of Surgery 07/1975; 62(7):576 - 580. DOI:10.1002/bjs.1800620720 · 5.21 Impact Factor